Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN) (OB-HTN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04838678 |
Recruitment Status :
Recruiting
First Posted : April 9, 2021
Last Update Posted : August 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension Obesity | Drug: Neuropeptide Y | Early Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Sympathetic Neural Patterns and Transduction in Obesity-associated Hypertension |
Actual Study Start Date : | July 18, 2021 |
Estimated Primary Completion Date : | September 2025 |
Estimated Study Completion Date : | September 2025 |

Arm | Intervention/treatment |
---|---|
Experimental: Healthy Control
Healthy age matched controls with no history of cardiovascular disease and normal bodyweight
|
Drug: Neuropeptide Y
intra-arterial infusion of neuropeptide Y |
Experimental: Hypertensive
Hypertensive adults who are not obese
|
Drug: Neuropeptide Y
intra-arterial infusion of neuropeptide Y |
Experimental: Obese
Obese adults who are not hypertensive
|
Drug: Neuropeptide Y
intra-arterial infusion of neuropeptide Y |
Experimental: Obese-hypertensive
Obese adults who are being treated for hypertension
|
Drug: Neuropeptide Y
intra-arterial infusion of neuropeptide Y |
- Blood flow measured by doppler ultrasound [ Time Frame: Acutely on the day of study ]brachial and femoral artery blood flow
- Muscle sympathetic nervous system activity [ Time Frame: Acutely on the day of study ]recording of sympathetic nervous system activity from the peroneal or radial nerve

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Control - BMI<30, age 18-55
- Hypertensive - BMI<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI>30, age 18-55 Obese-hypertensive- BMI>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring
Exclusion Criteria:
All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04838678
Contact: Christopher M Hearon, Ph.D. | 214-345-4624 | christopher.hearon@utsouthwestern.edu | |
Contact: Mary Childers | 214-345-6459 | marychilders@texashealth.org |
United States, Texas | |
University of Texas Southwestern Medical Center | Recruiting |
Dallas, Texas, United States, 75231 | |
Contact: CHristopher Hearon 815-540-5612 christopherhearon@texashealth.org |
Responsible Party: | Christopher Hearon, Assistant Instructor, University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT04838678 |
Other Study ID Numbers: |
STU2020-0749 |
First Posted: | April 9, 2021 Key Record Dates |
Last Update Posted: | August 10, 2022 |
Last Verified: | August 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
NPY |
Hypertension Obesity Overweight Overnutrition |
Nutrition Disorders Body Weight Vascular Diseases Cardiovascular Diseases |